U.S. Food and Drug Administration

Clinical Insights: October 2, 2017

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Verzenio™ (abemaciclib) – September 28, 2017 – The U.S. Food and Drug Administration approved Verzenio™ (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth…

Read More...

Clinical Insights: June 30, 2017

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval No new updates.   New Drug Shortage June 21, 2017 Cromolyn Sodium Inhalation Solution, USP (Currently in Shortage) New…

Read More...

Clinical Insights: June 2, 2017

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Rebinyn® (Coagulation Factor IX (Recombinant), GlycoPEGylated) – May 31, 2017 – Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application…

Read More...

Clinical Insights: May 26, 2017

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Kevzara® (sarilumab) – May 22, 2017 – Regeneron Pharmaceuticals, Inc. and Sanofi announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of…

Read More...

RxStrategies Clinical Insights — September 2015 Issue 1

Welcome to the first September edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Xuriden™ (uridine triacetate) September 4, 2015 — The U.S. Food and Drug Administration approved Xuriden™ (uridine triacetate), the first FDA-approved treatment for patients with…

Read More...